Since Altan et al. [42] reported that FOXO1 downregulation in a subset of gastric cancer cell lines inhibited 5-fluorouracil sensitivity, a JNK inhibitor may be used to restore the chemosensitivity to 5-fluorouracil through FOXO1 activation in the treatment of those gastric cancer patients. This evidence concerns the gene FOXO1 and gastric cancer.